{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:38:54Z","timestamp":1792571934028,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135\u00a0349 individuals treated with semaglutide and tirzepatide formulations and stratified them as \u201csuper responders\u201d (&amp;gt;15% weight loss), \u201cmoderate responders\u201d (5%\u201315% weight loss), \u201cminimal weight-loss group\u201d (&amp;lt;5% weight loss), and \u201cweight regainers.\u201d Ozempic, Wegovy, Mounjaro, and Zepbound had similar proportions of patients classified as moderate responders, ranging from 40% to 42%. Rates of super responders were highest for Zepbound (34%), followed by Wegovy (26%), Mounjaro (24%), and Ozempic (10%). Among moderate and super responders, the average weight after 1 year of treatment was similar to the average weight approximately 10 and 20\u2009years prior to treatment initiation, respectively. Compared with patients with minimal or moderate response, super responders were more likely to be younger (mean age 51\u2009years versus 55\u2009years), female (80% versus 58%\u201365%), and white (90% versus 80%). Baseline clinical characteristics enriched among super responders compared to the minimal response group included fibromyalgia (rate ratio [RR]: 0.2, P\u2009=\u2009.002) and osteoarthritis (RR = 0.5, P\u2009=\u2009.001) for Zepbound, and psoriasis (RR = 2.5, P\u2009=\u2009.03) for Wegovy. These results highlight significant heterogeneity in weight trajectories following sustained exposure to a GLP-1RA therapy and identify factors associated with increased weight loss, likely reflecting a combination of biological, behavioral, and social factors. These insights motivate further prospective analyses to help guide the development of more tailored weight-loss intervention strategies.<\/jats:p>","DOI":"10.1093\/biomethods\/bpag021","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:28:29Z","timestamp":1776756509000},"source":"Crossref","is-referenced-by-count":1,"title":["Decoding the hallmarks of GLP-1RA weight-loss super-responders"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-3214","authenticated-orcid":false,"given":"A J","family":"Venkatakrishnan","sequence":"first","affiliation":[{"name":"nference , Cambridge, MA 02142,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA 02142,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Murugadoss","sequence":"additional","affiliation":[{"name":"nference , Cambridge, MA 02142,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA 02142,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-9211","authenticated-orcid":false,"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[{"name":"nference , Cambridge, MA 02142,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA 02142,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2026102103473762400_bpag021-B1","author":"World Obesity Atlas 2025"},{"key":"2026102103473762400_bpag021-B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026102103473762400_bpag021-B3","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.cell.2025.06.010","article-title":"Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy","volume":"188","author":"Johansen","year":"2025","journal-title":"Cell"},{"key":"2026102103473762400_bpag021-B4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"2026102103473762400_bpag021-B5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102103473762400_bpag021-B6","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102103473762400_bpag021-B7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00125-025-06448-w","article-title":"Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study","volume":"68","author":"Heni","year":"2025","journal-title":"Diabetologia"},{"key":"2026102103473762400_bpag021-B8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.2337\/dc23-1135","article-title":"Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1\u20134","volume":"46","author":"Ma\u0142ecki","year":"2023","journal-title":"Diabetes Care"},{"key":"2026102103473762400_bpag021-B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102103473762400_bpag021-B10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-017177","article-title":"Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps","volume":"9","author":"Jeyakumar","year":"2024","journal-title":"BMJ Glob Health"},{"key":"2026102103473762400_bpag021-B11","doi-asserted-by":"crossref","first-page":"1382814","DOI":"10.3389\/fendo.2024.1382814","article-title":"Semaglutide for weight loss: unanswered questions","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026102103473762400_bpag021-B12","doi-asserted-by":"crossref","first-page":"e58227","DOI":"10.7554\/eLife.58227","article-title":"Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis","volume":"9","author":"Wagner","year":"2020","journal-title":"eLife"},{"key":"2026102103473762400_bpag021-B13","doi-asserted-by":"crossref","first-page":"e29812","DOI":"10.2196\/29812","article-title":"Analyzing patient trajectories with artificial intelligence","volume":"23","author":"Allam","year":"2021","journal-title":"J Med Internet Res"},{"key":"2026102103473762400_bpag021-B14","first-page":"124","article-title":"A generative foundation model for structured patient trajectory data","volume":"2024","author":"Akagi","year":"2024","journal-title":"AMIA Annu Symp Proc"},{"key":"2026102103473762400_bpag021-B15","doi-asserted-by":"publisher","first-page":"e13573","DOI":"10.1200\/JCO.2023.41.16_suppl.e13573","article-title":"Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma","volume":"41","author":"Pawlowski","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026102103473762400_bpag021-B16","doi-asserted-by":"crossref","first-page":"e64697","DOI":"10.2196\/64697","article-title":"A deep learning-enabled workflow to estimate real-world progression-free survival in patients with metastatic breast cancer: study using deidentified electronic health records","volume":"11","author":"Varma","year":"2025","journal-title":"JMIR Cancer"},{"key":"2026102103473762400_bpag021-B17","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1002\/ajh.27019","article-title":"Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data","volume":"98","author":"Silvert","year":"2023","journal-title":"Am J Hematol"},{"key":"2026102103473762400_bpag021-B18","doi-asserted-by":"crossref","first-page":"107695","DOI":"10.1016\/j.ymgme.2023.107695","article-title":"Retrospective study of propionic acidemia using natural language processing in Mayo Clinic electronic health record data","volume":"140","author":"Barman","year":"2023","journal-title":"Mol Genet Metab"},{"key":"2026102103473762400_bpag021-B19","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.patter.2021.100255","article-title":"Building a best-in-class automated de-identification tool for electronic health records through ensemble learning","volume":"2","author":"Murugadoss","year":"2021","journal-title":"Patterns (N Y)"},{"key":"2026102103473762400_bpag021-B20","doi-asserted-by":"publisher","author":"Murugadoss","year":"2024","DOI":"10.1101\/2024.06.20.24308896"},{"key":"2026102103473762400_bpag021-B21","author":"Devlin"},{"key":"2026102103473762400_bpag021-B22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102103473762400_bpag021-B23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41587-025-02932-1","article-title":"Are GLP-1s the first longevity drugs?","volume":"43","year":"2025","journal-title":"Nature Biotechnology"},{"key":"2026102103473762400_bpag021-B24","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cmet.2025.10.014","article-title":"Body-wide multi-omic counteraction of aging with GLP-1R agonism","volume":"37","author":"Huang","year":"2025","journal-title":"Cell Metab"},{"key":"2026102103473762400_bpag021-B25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.mayocp.2022.10.026","article-title":"Artificial intelligence-derived electrocardiogram assessment of cardiac age and molecular markers of senescence in heart failure","volume":"98","author":"Meenakshi-Siddharthan","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2026102103473762400_bpag021-B26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-022-29525-9","article-title":"Using deep learning to predict abdominal age from liver and pancreas magnetic resonance images","volume":"13","author":"Le Goallec","year":"2022","journal-title":"Nat Commun"},{"key":"2026102103473762400_bpag021-B27","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/mp.2017.62","article-title":"Brain age predicts mortality","volume":"23","author":"Cole","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2026102103473762400_bpag021-B28","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1111\/dom.70004","article-title":"Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026102103473762400_bpag021-B29","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"2026102103473762400_bpag021-B30","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"2026102103473762400_bpag021-B31","first-page":"e87823","article-title":"Impact of sleeping habits on the weight loss effect of oral glucagon-like peptide-1 receptor agonists among obese patients: an observational study in Japan","volume":"17","author":"Takakura","year":"2025","journal-title":"Cureus"},{"key":"2026102103473762400_bpag021-B32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41366-020-00728-8","article-title":"The association between sleep health and weight change during a 12-month behavioral weight loss intervention","volume":"45","author":"Kline","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2026102103473762400_bpag021-B33","doi-asserted-by":"crossref","first-page":"e0298411","DOI":"10.1371\/journal.pone.0298411","article-title":"Validity and reliability International Classification of Diseases-10 codes for all forms of injury: a systematic review","volume":"19","author":"Paleczny","year":"2024","journal-title":"PLoS One"},{"key":"2026102103473762400_bpag021-B34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12911-026-03345-z","article-title":"Automated abstraction of clinical parameters of multiple myeloma from real-world clinical notes using large language models","volume":"26","author":"Del Campo","year":"2026","journal-title":"BMC Med Inform Decis Mak"}],"container-title":["Biology Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomethods\/advance-article-pdf\/doi\/10.1093\/biomethods\/bpag021\/68118727\/bpag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag021\/68118727\/bpag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag021\/68118727\/bpag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:47:46Z","timestamp":1792568866000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomethods\/article\/doi\/10.1093\/biomethods\/bpag021\/8659582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/biomethods\/bpag021","relation":{},"ISSN":["2396-8923"],"issn-type":[{"value":"2396-8923","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"bpag021"}}